124 related articles for article (PubMed ID: 7907950)
1. Pharmacokinetics and metabolism of Taxotere (docetaxel).
Bruno R; Sanderink GJ
Cancer Surv; 1993; 17():305-13. PubMed ID: 7907950
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
Extra JM; Rousseau F; Bruno R; Clavel M; Le Bail N; Marty M
Cancer Res; 1993 Mar; 53(5):1037-42. PubMed ID: 8094996
[TBL] [Abstract][Full Text] [Related]
3. Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
Baille P; Bruno R; Schellens JH; Webster LK; Millward M; Verweij J; Montay G
Clin Cancer Res; 1997 Sep; 3(9):1535-8. PubMed ID: 9815840
[TBL] [Abstract][Full Text] [Related]
4. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
Gustafson DL; Long ME; Zirrolli JA; Duncan MW; Holden SN; Pierson AS; Eckhardt SG
Cancer Chemother Pharmacol; 2003 Aug; 52(2):159-66. PubMed ID: 12759775
[TBL] [Abstract][Full Text] [Related]
5. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
van Zuylen L; Verweij J; Nooter K; Brouwer E; Stoter G; Sparreboom A
Clin Cancer Res; 2000 Jul; 6(7):2598-603. PubMed ID: 10914699
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the linearity of docetaxel pharmacokinetics.
McLeod HL; Kearns CM; Kuhn JG; Bruno R
Cancer Chemother Pharmacol; 1998; 42(2):155-9. PubMed ID: 9654116
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
Burris H; Irvin R; Kuhn J; Kalter S; Smith L; Shaffer D; Fields S; Weiss G; Eckardt J; Rodriguez G
J Clin Oncol; 1993 May; 11(5):950-8. PubMed ID: 8098059
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of docetaxel.
Clarke SJ; Rivory LP
Clin Pharmacokinet; 1999 Feb; 36(2):99-114. PubMed ID: 10092957
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
Marchettini P; Stuart OA; Mohamed F; Yoo D; Sugarbaker PH
Cancer Chemother Pharmacol; 2002 Jun; 49(6):499-503. PubMed ID: 12107555
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials.
Bruno R; Riva A; Hille D; Lebecq A; Thomas L
Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S16-9. PubMed ID: 9435928
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
Loos WJ; Baker SD; Verweij J; Boonstra JG; Sparreboom A
Clin Pharmacol Ther; 2003 Oct; 74(4):364-71. PubMed ID: 14534523
[TBL] [Abstract][Full Text] [Related]
13. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Fossella FV
Semin Oncol; 1999 Jun; 26(3 Suppl 11):4-8. PubMed ID: 10458203
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.
Veyrat-Follet C; Bruno R; Olivares R; Rhodes GR; Chaikin P
Clin Pharmacol Ther; 2000 Dec; 68(6):677-87. PubMed ID: 11180028
[TBL] [Abstract][Full Text] [Related]
15. Phase II dose escalation: a novel approach to balancing efficacy and toxicity of anticancer agents. Japanese Docetaxel Ovarian Cancer Study Group.
Fujiwara K; Kohno I; Tanaka K; Ogita S; Sasaki Y; Hirabayashi K; Yakushiji M; Tsunematsu R; Terashima Y; Taguchi T; Ohashi Y; Noda K
Anticancer Res; 1999; 19(1B):639-44. PubMed ID: 10216469
[TBL] [Abstract][Full Text] [Related]
16. Early clinical studies with docetaxel. Docetaxel Investigators Group.
Aapro M; Bruno R
Eur J Cancer; 1995; 31A Suppl 4():S7-10. PubMed ID: 7577102
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel (Taxotere) administered in weekly schedules.
Greco FA
Semin Oncol; 1999 Jun; 26(3 Suppl 11):28-31. PubMed ID: 10458208
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer.
Kaye SB
Semin Oncol; 1995 Apr; 22(2 Suppl 4):30-3. PubMed ID: 7740329
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors.
Gonçalves A; Viret F; Ciccolini J; Genre D; Gravis G; Giovanini M; Camerlo J; Catalin J; Maraninchi D; Viens P
Clin Cancer Res; 2003 Jan; 9(1):102-8. PubMed ID: 12538457
[TBL] [Abstract][Full Text] [Related]
20. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
van Zuylen L; Sparreboom A; van der Gaast A; van der Burg ME; van Beurden V; Bol CJ; Woestenborghs R; Palmer PA; Verweij J
Clin Cancer Res; 2000 Apr; 6(4):1365-71. PubMed ID: 10778964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
